The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
TH Karlsen, N Sheron, S Zelber-Sagi, P Carrieri… - The Lancet, 2022 - thelancet.com
Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …
the face of European hepatology is changing due to the cure of viral hepatitis C and the …
[HTML][HTML] The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
…, HE Mark, M Villota-Rivas, A Palayew, P Carrieri… - Journal of …, 2022 - Elsevier
Background & Aims Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet
largely underappreciated liver condition which is closely associated with obesity and …
largely underappreciated liver condition which is closely associated with obesity and …
[HTML][HTML] Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV
…, S Buchbinder, C Caceres, PE Cahn, P Carrieri… - Nature …, 2021 - nature.com
Health systems have improved their abilities to identify, diagnose, treat and, increasingly,
achieve viral suppression among people living with HIV (PLHIV). Despite these advances, a …
achieve viral suppression among people living with HIV (PLHIV). Despite these advances, a …
[HTML][HTML] Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii
…, M Henry, F Armougom, H Richet, P Carrieri… - International journal of …, 2012 - nature.com
Background: Obesity is associated with increased health risk and has been associated with
alterations in bacterial gut microbiota, with mainly a reduction in Bacteroidetes, but few data …
alterations in bacterial gut microbiota, with mainly a reduction in Bacteroidetes, but few data …
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
M Olivier, A Langer√∏ d, P Carrieri, J Bergh… - Clinical cancer research …, 2006 - AACR
To investigate the clinical value of somatic TP53 mutations in breast cancer, we assembled
clinical and molecular data on 1,794 women with primary breast cancer with long-term …
clinical and molecular data on 1,794 women with primary breast cancer with long-term …
Leptin increase in multiple sclerosis associates with reduced number of CD4+CD25+ regulatory T cells
G Matarese, PB Carrieri, A La Cava… - Proceedings of the …, 2005 - National Acad Sciences
We analyzed the serum and cerebrospinal fluid (CSF) leptin secretion and the interaction
between serum leptin and CD4+ CD25+ regulatory T cells (TRegs) in naïve-to-therapy …
between serum leptin and CD4+ CD25+ regulatory T cells (TRegs) in naïve-to-therapy …
Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants
V De Rosa, M Galgani, A Porcellini, A Colamatteo… - Nature …, 2015 - nature.com
Human regulatory T cells (Treg cells) that develop from conventional T cells (Tconv cells)
following suboptimal stimulation via the T cell antigen receptor (TCR)(induced Treg cells …
following suboptimal stimulation via the T cell antigen receptor (TCR)(induced Treg cells …
Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy
…, M Savès, B Spire, V Cailleton, A Sobel, P Carrieri… - Aids, 2001 - journals.lww.com
In a sample of 277 patients included in the French APROCO cohort study who were initially
adherent at follow-up visit 4 months after initiation of a protease inhibitor-containing …
adherent at follow-up visit 4 months after initiation of a protease inhibitor-containing …
Regulatory T cell proliferative potential is impaired in human autoimmune disease
Abstract Human CD4+ CD25highCD127− FoxP3+ regulatory T (Treg) cells suppress
immune responses in vitro and in vivo. Reduced suppressive function and/or number of …
immune responses in vitro and in vivo. Reduced suppressive function and/or number of …
The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort
P Carrieri, V Cailleton, V Le Moing… - JAIDS Journal of …, 2001 - journals.lww.com
Objectives: Our objective was to describe the evolution of adherence to highly active
antiretroviral therapy (HAART) over a 20-month period and its relationship with virologic …
antiretroviral therapy (HAART) over a 20-month period and its relationship with virologic …